Recombinant human protein expressed in CHO cells
Catalog No. E860-40N
Catalog No. | Pack Size | Price (USD) | |
---|---|---|---|
E860-40N-50 | 50 ug | $171 | |
E860-40N-1000 | 1 mg | $1645 | |
E860-40N-BULK | BULK | Contact Us |
Overview:
EPO is predominantly synthesized and secreted by tubular and juxtatubular capillary, endothelial, and interstitial cells of the kidney. Approximately 10-15% of the total amount of EPO comes from extrarenal sources and is predominantly produced by hepatocytes and Kupffer cells of the liver. Approximately 40% of the molecular mass of EPO is due to its glycosylation. Glycosylation is an important factor determining the pharmacokinetic behaviour of EPO in vivo. Non-glycosylated Epo has an extremely short biological half life. Recombinant Human EPO is a glycosylated protein that runs at approximately 35 kDa owing to its glycosylation.
Gene Aliases:
Erythropoietin
Recombinant Human Erythropoietin-Alpha (EPO)
Genbank Number:
Storage, Stability and Shipping:
The lyophilized protein is stable for at least one year from date of receipt at -70oC. Upon reconstitution, this cytokine can be stored in working aliquots at 2o - 8oC for one month, or at -20oC for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.
Endotoxin Level:
<1.0 EU/μg of recombinant protein as determined by the LAL method.
Molecular Weight:
20.0 kDa
Reconstitution Protocol:
A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.
Sample Cell Assay Data:
Activity was determined by the dose-dependent proliferation assay using a factor-dependent human erythroleukemic cell line TF-1 and was found to be less than 0.2ng/ml.
Purity:
Recombinant Human EPO resolved on a 15% SDS-PAGE gel under reducing conditions and stained with Coomassie Brilliant Blue G-250.
There are no related publications available for this product.
Cancer
STAY CONNECTED
Fax: 1-604-232-4601